173 related articles for article (PubMed ID: 37398114)
1.
Yu Y; Cao WM; Cheng F; Shi Z; Han L; Yi JL; da Silva EM; Dopeso H; Chen H; Yang J; Wang X; Zhang C; Zhang H
bioRxiv; 2023 May; ():. PubMed ID: 37398114
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
3. FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.
Liu Y; Ao X; Jia Z; Bai XY; Xu Z; Hu G; Jiang X; Chen M; Wu H
Sci Rep; 2015 Mar; 5():8796. PubMed ID: 25740706
[TBL] [Abstract][Full Text] [Related]
4. Forkhead box K2 inhibits the proliferation, migration, and invasion of human glioma cells and predicts a favorable prognosis.
Wang B; Zhang X; Wang W; Zhu Z; Tang F; Wang D; Liu X; Zhuang H; Yan X
Onco Targets Ther; 2018; 11():1067-1075. PubMed ID: 29520156
[TBL] [Abstract][Full Text] [Related]
5. Sox9 mediated transcriptional activation of FOXK2 is critical for colorectal cancer cells proliferation.
Qian Y; Xia S; Feng Z
Biochem Biophys Res Commun; 2017 Jan; 483(1):475-481. PubMed ID: 28007600
[TBL] [Abstract][Full Text] [Related]
6. FOXK2, regulted by miR-1271-5p, promotes cell growth and indicates unfavorable prognosis in hepatocellular carcinoma.
Lin MF; Yang YF; Peng ZP; Zhang MF; Liang JY; Chen W; Liu XH; Zheng YL
Int J Biochem Cell Biol; 2017 Jul; 88():155-161. PubMed ID: 28506857
[TBL] [Abstract][Full Text] [Related]
7. FOXK2 promotes the proliferation of papillary thyroid cancer cell by down-regulating autophagy.
Li S; Wang P; Ju H; Zhu T; Shi J; Huang Y
J Cancer; 2022; 13(3):858-868. PubMed ID: 35154454
[TBL] [Abstract][Full Text] [Related]
8. Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.
Nestal de Moraes G; Khongkow P; Gong C; Yao S; Gomes AR; Ji Z; Kandola N; Delbue D; Man EP; Khoo US; Sharrocks AD; Lam EW
Oncogenesis; 2015 Sep; 4(9):e167. PubMed ID: 26344694
[TBL] [Abstract][Full Text] [Related]
9. FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma.
Zhang F; Ma X; Li H; Zhang Y; Li X; Chen L; Guo G; Gao Y; Gu L; Xie Y; Duan J; Zhang X
Int J Cancer; 2018 Jun; 142(12):2543-2557. PubMed ID: 29368368
[TBL] [Abstract][Full Text] [Related]
10. FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis.
Shan L; Zhou X; Liu X; Wang Y; Su D; Hou Y; Yu N; Yang C; Liu B; Gao J; Duan Y; Yang J; Li W; Liang J; Sun L; Chen K; Xuan C; Shi L; Wang Y; Shang Y
Cancer Cell; 2016 Nov; 30(5):708-722. PubMed ID: 27773593
[TBL] [Abstract][Full Text] [Related]
11. FOXK2 regulates PFKFB3 in promoting glycolysis and tumorigenesis in multiple myeloma.
Liu X; Tang N; Liu Y; Fu J; Zhao Y; Wang H; Wang H; Hu Z
Leuk Res; 2023 Sep; 132():107343. PubMed ID: 37356282
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA tumor protein 53 target gene 1 promotes cervical cancer development via regulating microRNA-33a-5p to target forkhead box K2.
Liao D; Liu X; Yuan X; Feng P; Ouyang Z; Liu Y; Li C
Cell Cycle; 2022; 21(6):572-584. PubMed ID: 35090377
[TBL] [Abstract][Full Text] [Related]
13. Emerging roles of FOXK2 in cancers and metabolic disorders.
Xing X; Que X; Zheng S; Wang S; Song Q; Yao Y; Zhang P
Front Oncol; 2024; 14():1376496. PubMed ID: 38741782
[TBL] [Abstract][Full Text] [Related]
14. FOXK2 transcription factor and its roles in tumorigenesis (Review).
Wang Z; Liu X; Wang Z; Hu Z
Oncol Lett; 2022 Dec; 24(6):461. PubMed ID: 36380871
[TBL] [Abstract][Full Text] [Related]
15. FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway.
Feng H; Jin Z; Liang J; Zhao Q; Zhan L; Yang Z; Yan J; Kuang J; Cheng X; Qiu W
Oncogene; 2021 Oct; 40(42):6115-6129. PubMed ID: 34489549
[TBL] [Abstract][Full Text] [Related]
16. Regulation and roles of FOXK2 in cancer.
Kang Y; Zhang K; Sun L; Zhang Y
Front Oncol; 2022; 12():967625. PubMed ID: 36172141
[TBL] [Abstract][Full Text] [Related]
17. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
Rutkovsky AC; Yeh ES; Guest ST; Findlay VJ; Muise-Helmericks RC; Armeson K; Ethier SP
BMC Cancer; 2019 May; 19(1):491. PubMed ID: 31122207
[TBL] [Abstract][Full Text] [Related]
18. Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes.
Chen S; Jiang S; Hu F; Xu Y; Wang T; Mei Q
Oncol Rep; 2017 Apr; 37(4):2335-2347. PubMed ID: 28260088
[TBL] [Abstract][Full Text] [Related]
19. SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells.
Nestal de Moraes G; Ji Z; Fan LY; Yao S; Zona S; Sharrocks AD; Lam EW
Oncogenesis; 2018 Mar; 7(3):29. PubMed ID: 29540677
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
